Clover Health Q2 2026: AI-Driven Growth, Rising Membership, and a Clearer Path to 2027

Clover Health Investments, Corp. (ticker: CLOV) surfaced its Q2 2026 results with a reminder that in health care finance, the math isn’t just about patients served but about the economics of a full-risk Medicare Advantage model. The company reported GAAP net income of $28 million for the quarter, an improvement of $39 million year over year, alongside a Medicare Advantage membership of 157,309—up 48% from the prior year. Revenue reached $743 million, up 56% year over year, with gross profit of $153 million (up 54%) and Adjusted EBITDA of $41 million (up 139%). If you’re scanning for EPS or an EPS consensus, the filing here doesn’t print a per-share figure; it does, however, lay out a narrative where the earnings power is evolving under a technology-enabled care framework—one that Clover says is being amplified by its Clover Assistant AI platform and a potential tilt toward a 4.5 Star CMS payment year.

Key operating highlights

GAAP net income: $28 million for Q2 2026, up $39 million versus year-ago quarter.
MA membership: 157,309 members, +48% YoY.
Total revenues: $743 million, +56% YoY.
Consolidated gross profit: $153 million, +54% YoY.
Adjusted EBITDA: $41 million, +139% YoY.

Guidance and the revenue forecast for 2026

Clover raised its full-year 2026 outlook with a focus on growth in MA membership and stronger unit economics. The company guides for an average Medicare Advantage membership of 156,000 to 158,000, representing roughly 47% growth year over year at the midpoint. Revenue is forecast between $2.92 billion and $3.00 billion, at the midpoint about a 54% rise YoY. Consolidated gross profit is expected to land between $525 million and $555 million (midpoint ~ $540 million, ~52% YoY growth), and Adjusted EBITDA is targeted at $70 million to $85 million. GAAP net income for the year is projected in the range of $20 million to $35 million.

For readers tracking EPS, the quarter’s press release emphasizes GAAP earnings and Adjusted EBITDA, not a standalone EPS figure in this excerpt. Analysts often compare EPS to an EPS consensus to gauge an earnings surprise, but here the narrative centers on growth in MA membership and the economics of the technology-enabled care model as the driver of profitability, not a single quarterly per-share statistic. The revenue forecast and margin targets, however, suggest a credible path to higher earnings leverage if cohorts mature as planned.

The underlying thesis: why this might matter beyond CLOV

Clover’s business is anchored in a full-risk Medicare Advantage model. The growth engine isn’t just more insured lives; it’s higher-quality cohort economics, better engagement through digital tools, and the ability to keep more of the economics when outcomes improve. The company frames the progress as “cohort development” and improved clinical engagement—essentially, more members maturing into higher-margin economics as the platform matures.

The message from management—particularly through the commentary on Clover Assistant and the potential for a 4.5 Star payment year—hints at a bull case in which AI-assisted care translates into earlier interventions, fewer costly escalations, and better risk-adjusted margins. If that dynamic persists, CLOV’s margin trajectory could outpace peers who lag on digital enablement or who rely more on fee-for-service models rather than full risk. It’s not just marketing jargon: the ability to translate clinical improvements into economics is the critical variable in a sector where patients, payers, and regulators tilt like a three-way nerve strike.

From a sector perspective, Clover’s Q2 results add to a narrative that a subset of Medicare Advantage players are betting on in-house risk-taking paired with AI-enabled care pathways. If Clover proves the model scalable, expect peers to intensify investment in data science, member retention, and care-management platforms. The question for managers and investors isn’t merely “are prices rising?” but “are we realizing the incremental value of the tech-enabled care stack in the cost base and in patient outcomes?”

Risks and caveats

The pivot to higher-margin outcomes rests on sustained membership growth, favorable risk pools, and the effectiveness of the Clover Assistant and related care-management tools. As with any full-risk model, cost overruns, adverse selection pressures, or shifts in CMS payment policy could compress margins. The absence of a disclosed EPS figure in the release means investors will likely compare CLOV’s reported GAAP earnings and Adjusted EBITDA to consensus expectations through those lenses rather than a clean per-share statistic. In short, the path to profitable expansion hinges on how well the platform converts clinical gains into cash flow, not merely on top-line growth.

Notes on metrics and investor focus

While the document provides GAAP net income, gross profit, and Adjusted EBITDA, it does not present an EPS figure or an explicit EPS consensus. Analysts who care about quarterly surprises will be watching to see whether the cadence of earnings surprises—positive or otherwise—emerges as the business scales. The revenue forecast, MA membership trajectory, and the margin guidance will be the anchor points for evaluating whether CLOV’s AI-enhanced care model can reliably convert stronger top-line growth into sustained earnings power.

Conclusion

Clover Health’s Q2 2026 results signal a company that’s stacking up members and cash flow in a way the market has asked for: credible revenue growth, improving profitability metrics, and a forward-looking plan that leans into AI-enabled care. The real test will be how durable the cohort economics prove to be and whether the 4.5 Star-year flexibility translates into sustained cash generation. If CLOV can keep the momentum in MA membership while converting clinical gains into dependable earnings power, the stock’s narrative may shift from a growth bet to a growth-with-margin story—an outcome that would make EPS skeptics reconsider their odds and EPS consensus peers take notes.